Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Multiple vs. Culprit vessel MI in Cardiogenic Shock: Anything New?

The Shock Trial, the one that set revascularization as the standard strategy to treat all STEMI and cardiogenic shock lesions, had not been discussed for nearly 20 years. 

Infartos en Shock: Múltiples vasos vs solo vaso culpable ¿Hay novedades?

The CULPRIT-SHOCK was presented at TCT 2017 (and also in NEJM), and again this one study changed the standard completely, since we went back to treating only the culprit vessel (at least as first) in shock MI. 

Now more news come out based on MI and cardiogenic shock, since we were lacking evidence on patients receiving mechanical circulatory support. 

Between July 2016 and December 2019, all patients undergoing MI and cardiogenic shock from 57 hospitals taking part in the registry were included. 

Those with multivessel disease were analyzed according to whether they received complete revascularization or only culprit vessel revascularization during the index procedure. 


Read also: Compare-Acute Sub-Study: Natural History of Non-Culprit Lesions in MI.


Of 198 patients with multivessel disease, 126 received multivessel PCI during index procedure (64%) and only 72 got culprit vessel PCI (36%). Baseline characteristics in both groups were similar as regards sex, diabetes, age, prior PCI, prior CABG or prior MI. 

Patients undergoing multivessel PCI showed worse impairment of cardiac output and worse lactate clearance at 12 hours after procedure. However, at 24 hours, these differences levelled off between the groups. 

Survival (69.8% vs 65.3%; p=0.51) and acute kidney injury rates resulted similar between groups (29.9% vs 34.2%; p=0.64). These two points, especially survival, had been the ones that tilted the scales in the CULPRIT-SHOCK in favor of treating only the culprit vessel. 


Read also: Estimating the Risk of Infection for Healthcare Personnel.


The difference in this study was the early use of mechanical circulatory support (Impella) in both groups. In fact, over 70% of patients were treated with the device before PCI and the rest during and after procedure. 

The use of Impella might explain the difference between these outcomes and those of the CULPRIT-SHOCK.

Conclusion

Multivessel patients undergoing MI and cardiogenic shock who receive early mechanical circulatory support can receive selective complete revascularization at index procedure with similar survival and kidney injury rates as patients who receive culprit vessel PCI.

Original Title: Multi- Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock.

Reference: Alejandro Lemor et al. J Am Coll Cardiol Intv 2020, article in press. doi: 10.1016/j.jcin.2020.03.012.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...